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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• Benzodiazepines (BZDs) are not only used as a
treatment for anxiety and depression (besides
epilepsy), but also inappropriately for chronic
insomnia, pain, somatic illnesses [1] and
uncontrollable stress.
• In spite of lack of effectiveness and adverse
health consequences in chronic BZD use, over
50% are long-term users.
• The relative importance of sociodemographic,
psychological and physical determinants of BZD
use in general and inappropriate use has never
been investigated in a comprehensive,
multivariable model.
WHAT THIS STUDY ADDS
• BZDs were used by a considerable proportion of
the NESDA participants and BZD use was rarely in
accordance with all guidelines, mainly because of
an extended duration of use.
• Mentally or physically vulnerable subjects were
most likely to use BZDs as well as to use it
inappropriately.
• Clinicians should be vigilant when initiating BZD
prescriptions for vulnerable subjects, particularly
when patients are chronically ill and old, as those
subjects are at high risk of inappropriate use.
AIM
Results on determinants of benzodiazepine (BZD) use in general and
inappropriate use were inconsistent and mostly univariate. The relative
importance of sociodemographic, psychological and physical determinants has
never been investigated in a comprehensive, multivariate model.
METHODS
We included 429 BZD users and 2423 non-users from the Netherlands Study of
Depression and Anxiety (NESDA) in order to investigate sociodemographic,
psychological and physical determinants of BZD use and inappropriate use by
logistic and linear regression analyses.
RESULTS
BZDs were used by a considerable proportion of the 2852 NESDA participants
(15.0%). BZD use was independently associated with older age, singleness,
unemployment, treatment in secondary care, higher medical consumption
(more severe) anxiety, depression (OR [95% CI] = 1.95 [1.29, 2.93]), comorbidity,
insomnia, SSRI (OR [95% CI] = 2.05 [1.55, 2.70]), TCA and other antidepressant
(OR [95% CI] = 2.44 [1.64, 3.62]) use. Overall, BZD use was rarely in accordance
with all guidelines, mainly because most users (82.5%) exceeded the
recommended duration of safe use. Inappropriate use was independently
associated with older age (b = 0.130) and chronic illnesses (b = 0.120). Higher
scores on agreeableness were associated with less inappropriate use.
CONCLUSIONS
Mentally or physically vulnerable subjects were most likely to use BZDs. The
most vulnerable (i.e. the old and physically ill) BZD users were at highest risk of
inappropriate BZD use. Without further evidence of the effectiveness of BZDs
in long-term use, caution in initiating BZD prescriptions is recommended,
particularly when patients are chronically ill and old, as those are most likely to
display inappropriate use.
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Introduction
Benzodiazepines (BZDs) are commonly prescribed as a
treatment for anxiety and insomnia [2–5]. Remarkably,
BZDs are also inappropriately used for pain [6], somatic
illnesses [1] and less specific stress responses [7, 8].
Although there is still controversy about the potential for
abuse with BZDs, dependence, withdrawal symptoms and
side effects, prevalence rates of BZD use are high and vary
between 7.5% and 21.3% across countries [9–12]. Due to
these high prevalence rates it is informative to obtain a
profile of the average BZD user. Specific subject character-
istics such as sociodemographic factors (female sex [5,
12–15], older age [3, 5, 12–16], lower education [14], and
unemployment [12, 13, 15]), psychological characteristics
(worse mental health [3, 13, 15–17], antidepressant use
[13, 18], and elevated neuroticism [14, 15, 17]) and physical
health factors (chronic illnesses or other physical health
problems [1, 13–18], higher medical consumption [18],
and pain complaints [6]) were found to be associated with
BZD use in previous studies. A number of these variables
[5, 12, 13], but not all [14, 15, 17], were identified as impor-
tant correlates of BZD use in the majority of studies.
Several studies did not look at the determinants inde-
pendently by using a multivariate analysis [3, 5, 14, 17, 18]
and no joint investigation of all determinants has been
conducted yet.
When BZDs are used as indicated, i.e. at standard
therapeutic doses, during a short time period, and only
one type of BZD at a time, treatment is usually without
strong side effects [19]. Inappropriate BZD use is accom-
panied by adverse health consequences including cogni-
tive impairment, risk of falling, traffic accidents, and
dependence [6, 20–23]. Further, there is little evidence for
the effectiveness of BZDs during chronic use [24]. There-
fore, several national and international guidelines were
formed that, although showing some differences, all
recommended a conservative practice of prescription,
including short-term use [25–27]. However, more than 20
years after the notion that long-term BZD use should be
discouraged, still more than 50% of current BZD users are
chronic users (i.e. using BZDs for more than 3 months)
[12, 28, 29]. To prevent inappropriate use, it is important to
determine which users become inappropriate users. To
date, the determinants of inappropriate use have not
been investigated. Only the determinants of long-term
use have been studied, yet with inconsistent results and
without considering the other aspects of inappropriate
use (i.e. dosage and number of BZD types used). In those
studies, sex [29–31], age [28–33], education [32], psycho-
pathology [32–34], physical health [30, 33, 34], pain com-
plaints [34], daily BZD use [28], use of higher potency
BZDs [31] and antidepressants [33] were identified as
correlates of long-term BZD use.
To the best of our knowledge, we are the first study to
investigate the relative importance of a comprehensive set
of potential determinants of BZD use and inappropriate
use in a study among 2852 subjects at various stages of
psychopathology participating in the Netherlands Study
of Depression and Anxiety (NESDA). We first explored the
sociodemographic, psychological and physical correlates
of BZD use. Second, we investigated (the determinants of )




Subjects participated in the baseline assessment of the
Netherlands Study of Depression and Anxiety (NESDA), an
8-year longitudinal cohort study of 2981 respondents
aged 18 to 65 years [35]. NESDA was designed to be rep-
resentative of individuals with depressive and/or anxiety
disorders in different health care settings and develop-
mental stages of illness [35]. Psychiatric status did not
seem to be predictive of the initial (non)-response in the
NESDA study. (Non)-response was driven by age and sex,
i.e. older women more often participated in the NESDA
study and young men less often [35]. Subjects were
recruited from the community, general practice and spe-
cialized mental health care institutions throughout the
Netherlands.They completed a medical exam,an in-person
interview, and several self-report questionnaires.The study
protocol was approved by the Ethics Review Board of each
participating centre and all subjects signed an informed
consent at the baseline assessment.
We excluded subjects with one or more missing values
on BZD use, inappropriate use, sociodemographic, psycho-
logical or physical characteristics (n = 94). An exception
was made for missing values on the Insomnia Rating Scale
(IRS) where mean imputation was used due to the high
number of missing values (n = 300). We also excluded sub-
jects with epilepsy (n = 29), as epilepsy is an indication that
justifies prolonged BZD use [36].
To obtain an indication of the main determinants of
BZD use (aim 1), two groups were defined: subjects who
reported BZD use in the month prior to the baseline inter-
view (‘BZD users’, n = 429) and those reporting no use of
BZDs in the last month (‘non-users’, n = 2423). For the inves-
tigation of adequacy of BZD use (aim 2) only BZD users
were considered and further categorized according to
adequacy of BZD use.
Benzodiazepine use
Two indicators of BZD use were investigated: BZD use and
appropriateness of BZD use.
BZD use during the month prior to baseline inter-
view was registered by observation of drug containers
brought to the interview (in 73.4% of cases) or self-report
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(in 26.6% of cases). Information was collected about
name, dose, number of tablets and duration of BZD use.
Medication was coded according to the ATC/DDD (Ana-
tomical Therapeutic Code/Defined Daily Dose) system
developed by the World Health Organization (WHO) col-
laborating Centre for Drug Statistics Methodology. BZDs
were classified as ATC-coded groups N05BA, N05CD,
N05CG, and N03AE01. The so called ‘Z-drugs’, of which in
the Netherlands only zopiclone and zolpidem (ATC
code N05CF) are available, were also included in our
analyses, as studies on long-term adverse effects, with-
drawal and tolerance development for these drugs are
still lacking. The daily BZD dose was computed according
to the coding system of the ATC and DDD system [37].
The Mean Daily Dose was calculated by dividing indi-
vidual daily doses (in mg) of BZDs by the DDD for the
particular BZD [38]. For patients using BZDs other than
diazepam, an equivalent daily dose was calculated with
the conversion tables commonly used by general practi-
tioners’ (GPs) [39] and 10 mg diazepam were regarded
equivalent to 1 mg alprazolam, 10 mg bromazepam,
0.25 mg brotizolam, 20 mg clobazam, 20 mg chlordiazep-
oxide, 13.3 mg clorazepate, 8 mg clonazepam, 30 mg
flurazepam, 1 mg loprazolam, 2 mg lorazepam, 1 mg
lormetazepam, 7.5 mg midazolam, 10 mg nitrazepam,
33 mg oxazepam, 20 mg prazepam, 20 mg temazepam,
20 mg zolpidem and 13 mg zopiclone. Dosages were
summed when more than one BZD was used. Types of
BZDs were subdivided into short acting (t1/2 < 24 h) and
long acting (t1/2  24 h) BZDs. Duration of use was cat-
egorized as short-term (3 months) or long-term (>3
months). The number of different types of BZDs used was
categorized into 1, 2, or 3. BZDs were further divided into
anxiolytics (ATC code N05BA, n = 263) and hypnotics (ATC
codes N05CD and N05CF, n = 147).
Appropriateness of use was based on the Dutch
practice guidelines for anxiety and insomnia [26, 27]
and the British National Institute of Health and Clinical
Excellence treatment guidelines for general practitioners
[25]. The following criteria for appropriate use were
derived:
1 mean daily dosage  DDD as defined by the World
Health Organization.
2 duration of benzodiazepine use 3 months in case of no
concomitant antidepressant (AD) use and 2 months in
case of concomitant AD use.
3 only one type of BZDs is used at a time.
Based on the number of appropriate criteria not met
by a subject, an inappropriateness score (range 0–3) was
calculated.An inappropriateness score of 0 indicated that a
subject met all three appropriateness criteria (i.e. appropri-
ate use) whereas an inappropriateness score of 3 indicated




Based on previous studies, various potential determinants
of BZD use and adequacy of BZD use were included
and grouped into sociodemographic characteristics (age,
gender, education, marital status and work status), psycho-
logical characteristics (current psychopathology, health
care setting, severity of anxiety or depression symptoms;
insomnia; antidepressant use, and personality traits) and
physical characteristics (number of chronic diseases,
medical consumption, pain complaints and smoking)
[5, 12–15, 29, 32–34, 40].
Sociodemographic characteristics Gender, age, education
level (in years), work status (employed vs. unemployed),
and partner status (living with partner vs. single) were
reported in the baseline interview.
Psychological characteristics In NESDA, depressive (dys-
thymia or Major Depressive Disorder, MDD) and anxiety
(panic disorder with or without agoraphobia, generalized
anxiety disorder or social phobia) diagnoses were mea-
sured by the Composite International Diagnostic Interview
(CIDI, life time version 2.1), which classifies diagnoses
according to the DSM-IV criteria. Current diagnoses were
defined as those in the last year.The severity of generalized
anxiety and panic symptoms were assessed with the Beck
Anxiety Inventory (BAI) [41].The presence of insomnia was
determined using the Insomnia Rating Scale (IRS) [42].
The severity of depressive symptoms was measured by
the cognitive/mood scale of the Inventory of Depressive
Symptomatology Self Report (IDS-SR) [43]. In order to
avoid overlap with the BAI and IRS, we did not include the
anxiety/arousal and sleep scales of the IDS-SR. So as to
make the score of BAI, IDS-SR and IRS comparable, z-scores
were calculated and z transformed values were used
for regression analyses. Personality traits were assessed
with the Neuroticism Extraversion Openness-Five Factor
Inventory (NEO-FFI), a 60-item questionnaire measuring
five personality domains: neuroticism, extraversion, agree-
ableness, conscientiousness and openness to experience
[44]. Antidepressant use was reported during the inter-
view.The ATC-coded groups N06AA, N06AB, N06AF, N06AX
and N06AG were classified as antidepressants.
Physical characteristics An inventory of somatic diseases
was made by detailed questions of the presence of the
following chronic illnesses: chronic lung disease, heart
condition, diabetes mellitus, stroke, arthritis, rheumatism,
cancer, hypertension, ulcer, intestinal problems, liver
disease, chronic fatigue syndrome, allergy, thyroid gland,
head injury or other injuries. Based on the number of
chronic diseases a subject suffered from, a score ranging
from 0 to 17 was calculated. Medical consumption was
defined as the number of GP consultations in the 6 months
prior to the interview, as assessed with the Perceived Need
Correlates of benzodiazepine use
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for Care Questionnaire (PNCQ) [45]. Pain complaints were
measured with the Chronic Graded Pain Scale and pain
severity (consisting of pain intensity and disability) was
summarized by the Chronic Pain Grade according to Korff
et al., which is a score ranging from 0 to 4 [46]. Smoking
was reported during the interview.
Statistical analyses
Sample characteristics and characteristics of BZD use were
expressed by frequencies, means or medians, and com-
pared using c2 statistics (for categorical variables), analysis
of variance (ANOVA, for normally distributed, continuous
variables), and Mann–Whitney U-test (for non-normally
distributed, continuous variables). Non-normally distrib-
uted values were naturally log transformed for regression
analyses.
Univariate logistic and linear regression analyses were
carried out to identify correlates of BZD use (vs. non-use
as the reference category) and inappropriate use (appro-
priateness score ranging from 0–3). Odds ratios with 95%
confidence intervals (OR [95% CI]) and standardized betas
(b) were provided as outcome measures. All independent
variables with P < 0.10 in univariate analyses were entered
in the multivariate regression models. The P value was set
at P < 0.10 (instead of P < 0.05) in order to avoid missing
important determinants of BZD use that do not reach sig-
nificance in univariate analysis at P < 0.05 but will when
correcting for possible confounders in multivariate analy-
ses. The following variables were considered: (1) demo-
graphic variables: gender, age, education level, work status,
and marital status; (2) psychological characteristics: current
psychopathology, health care setting, severity of anxiety
and depression symptoms, insomnia, antidepressant use
and personality traits; and (3) physical characteristics:
number of chronic diseases, medical consumption, pain
complaints and smoking. The analysis was adjusted for
sex and age. Significance in the multivariate model was
inferred at P < 0.05.
Finally, we compared anxiolytic and hypnotic users
on possible characteristics of BZD use using c2 statistics
Table 1




n = 429 P value
Sociodemographics
Sex (% female) 66.1 68.1 0.43
Age (years) 41.2 (40.7–41.7) 46.3 (45.0–47.5) <0.001
Marital status (% single) 29.6 36.4 0.005
Employment status (% not working) 28.4 51.7 <0.001
Education level (years) 12.0 (10.0–15.0) 11.0 (9.0–15.0) <0.001
Treatment in secondary care (%) 24.2 49.0 <0.001
Physical health
Medical consumption 2.0 (1.0–3.0) 3.0 (2.0–5.0) <0.001
Chronic illnesses 1.8 (1.8–1.9) 2.5 (2.3–2.6) <0.001
Pain 1.5 (1.5–1.6) 2.1 (2.0–2.2) <0.001
Smoking (%) 28.9 24.2 0.05
Psychological characteristics
Current diagnosis (%) <0.001
MDD only 15.1 17.5
Anxiety only 14.6 18.2
Comorbid disorder 23.1 49.0
IRS 8.0 (4.0–10.0) 10.0 (8.0–15.0) <0.001
BAI 8.0 (3.0–16.0) 20.0 (10.0–28.0) <0.001
IDS-SR mood/cognition scale 5.0 (2.0–11.0) 12.0 (6.0–16.5) <0.001





Neuroticism 23.5 (23.1–23.8) 28.7 (27.9–29.6) <0.001
Extraversion 25.4 (25.1–25.7) 21.8 (21.1–22.4) <0.001
Openness 26.4 (26.2–26.7) 25.3 (24.7–25.9) <0.001
Agreeableness 31.9 (31.7–32.1) 31.2 (30.7–31.7) 0.02
Conscientiousness 30.5 (30.2–30.7) 28.8 (28.2–29.3) <0.001
BAI indicates Beck’s anxiety index; IDS-SR indicates Inventory of Depressive Symptomatology; IRS indicates insomnia rating scale; MDD indicates major depressive disorder; SSRI
indicates selective serotonin re-uptake inhibitor; TCA indicates tricyclic antidepressant. Means (95% confidence intervals) are given for age, chronic illnesses, pain and personality
traits. Medians (interquartile range) are given for education level, medical consumption IRS, BAI and IDS as these values are not normally distributed. Percentages are given for
categorical variables. P is derived by analysis of variance (ANOVA) for quantitative, normally distributed variables, Mann–Whitney U-test for continuous, non-normally distributed
variables or c2 statistics for categorical variables. Significance is inferred at P < 0.10.
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(for categorical variables), ANOVA (for normally distributed,
continuous variables), and Mann–Whitney U-test (for non-
normally distributed, continuous variables) to find out
whether there would be group differences. Significance
was inferred at P < 0.05. All analyses were conducted with
SPSS 16.0 for Windows.
Results
BZD use
Of the 2852 subjects, 429 (15.0%) had used a BZD in the
past month.Table 1 shows the sociodemographic, psycho-
logical and physical characteristics of BZD users as com-
pared with non-users.
BZD users were older (mean 46.3 vs. 41.2 years, P <
0.001), more likely to be single (36.4% vs. 29.6%, P = 0.005)
and more likely to be unemployed (51.7% vs. 28.4%,
P < 0.001). Further, BZD users displayed worse physical
(3.0 vs. 2.0 medical consumption, P < 0.001) and psycho-
logical health (BAI score of mean 20.0 vs. 8.0, respectively,
P < 0.001).
Table 2 shows the effect of putative correlates of BZD
use as opposed to non-use among all subjects. Univariate
P values of these analyses are shown in Table 1 which
comprises group comparisons conducted with ANOVAs. An
ANOVA results in exactly the same P value as a regression
analysis.
In multivariate analyses, the following variables
were significant correlates of BZD use: older age
(OR = 1.48), singleness (OR = 1.34), unemployment
(OR = 1.56), treatment in secondary care (OR = 1.55),
higher medical consumption (OR = 1.41), a diagnosis
of depression (OR = 1.56), anxiety (OR = 1.95) and comor-
bidity (OR = 1.78), higher scores on the IRS (OR = 1.35)
and BAI (OR = 1.65) questionnaires, use of SSRIs
(OR = 2.05), TCAs (OR = 1.84) and other antidepressants
(OR = 2.44).
In the comparison between anxiolytic and hypnotic
users, groups were similar on most variables, except of
the following: Anxiolytic users were younger (45.3 vs. 47.8,
P = 0.04), had more often a diagnosis of anxiety (25.2
vs. 14.9%, P = 0.02), less often a diagnosis of depression
(15.9 vs. 28.9%, P = 0.009), had lower scores on insomnia
Table 2
Determinants of benzodiazepine use as opposed to non-use: results from univariate and multivariate logistic regression analyses (n = 2852)
Univariate analysis odds
ratio (95% CI) P value*
Multivariate analysis
odds ratio (95% CI) P value**
Sociodemographics
Sex (female) 1.09 (0.88, 1.36) 0.43 1.09 (0.84, 1.42) 0.53
Age (per 10 years) 1.34 (1.22, 1.48) <0.001 1.48 (1.34, 1.63) <0.001
Marital status (single) 1.36 (1.10, 1.69) 0.005 1.34 (1.05, 1.71) 0.02
Employment status (not working) 2.71 (2.20, 3.33) <0.001 1.56 (1.22, 1.99) <0.001
Education level (years) 0.30 (0.20, 0.43) <0.001 0.89 (0.56, 1.43) 0.64
Health care setting (secondary care) 3.00 (2.43, 3.71) <0.001 1.55 (1.16, 2.07) 0.003
Physical health
Medical consumption 2.39 (2.04, 2.79) <0.001 1.41 (1.17, 1.69) <0.001
Chronic illnesses 1.28 (1.20, 1.35) <0.001 1.02 (0.95, 1.11) 0.54
Pain 1.63 (1.49, 1.79) <0.001 1.09 (0.97, 1.23) 0.13
Smoking 0.79 (0.62, 1.00) 0.05 0.96 (0.73, 1.26) 0.77
Psychological characteristics
Current diagnosis
MDD only 1.19 (0.91, 1.56) 0.21 1.56 (1.02, 2.40) 0.04
Anxiety only 1.30 (1.00, 1.71) 0.06 1.95 (1.29, 2.93) 0.001
Comorbid disorder 3.20 (2.59, 3.95) <0.001 1.78 (1.17, 2.70) 0.008
IRS 2.13 (1.85, 2.45) <0.001 1.35 (1.16, 1.56) 0.001
BAI 2.72 (2.37, 3.13) <0.001 1.65 (1.34, 2.03) <0.001
IDS-SR mood/cognition scale 2.29 (2.00, 2.62) <0.001 0.90 (0.72, 1.13) 0.36
Antidepressant use (past month)
SSRI 3.27 (2.60, 4.12) <0.001 2.05 (1.55, 2.70) <0.001
TCA 3.06 (1.88, 4.98) <0.001 1.84 (1.07, 3.16) 0.03
Others 3.74 (2.67, 5.24) <0.001 2.44 (1.64, 3.62) <0.001
Personality characteristics
Neuroticism 1.07 (1.06, 1.08) <0.001 0.99 (0.97, 1.02) 0.61
Extraversion 0.93 (0.92, 0.95) <0.001 1.00 (0.98, 1.02) 0.78
Openness 0.97 (0.95, 0.99) <0.001 0.99 (0.97, 1.01) 0.29
Agreeableness 0.98 (0.96, 1.00) 0.02 1.01 (0.99, 1.04) 0.26
Conscientiousness 0.96 (0.94, 0.97) <0.001 1.00 (0.98, 1.02) 0.92
BAI indicates Beck’s anxiety index; IDS indicates Inventory of Depressive Symptomatology; IRS indicates insomnia rating scale; MDD indicates major depressive disorder; SSRI indicates.
selective serotonin re-uptake inhibitor; TCA indicates tricyclic antidepressant. Significance is inferred at P < 0.10. *The P values were obtained by univariate analyses. **The P values
were obtained by multivariate analyses.
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(9.0 vs. 13.0, P  0.001) and higher scores on agreeableness
(31.8 vs. 30.5, P = 0.02, data not shown).
Appropriateness of BZD use
In Table 3, we present the characteristics of BZD use
among the 429 BZD users. The median daily dosage used
was 2.5 mg of diazepam equivalents (interquartile range
[IQR] 0.7–6.0) and the median duration of BZD use was
24 months (IQR 5.0–84.0). The most frequently used BZD
was oxazepam (44.3%), followed by temazepam (14.9%),
diazepam (14.7%) and alprazolam (6.1%).
Only 17.5% of all BZD users took BZDs for the appropri-
ate duration of 3 months whereas 82.5% of users took BZDs
for a much longer period. The remaining appropriateness
criteria were met more frequently.The majority of the BZD
users (86.0%) did not exceed the recommended DDD as
defined by the WHO and 84.4% of users had only a prescrip-
tion for one type of BZD at a time. However, mainly due to
the high duration of BZD use of most users, only 15.2% of
BZD users met all three appropriateness criteria, whereas
64.3% met two criteria,13.8% met one and 6.8% of users did
not meet any criterion (highly inappropriate use).
Table 4 shows the effect of potential correlates of inap-
propriate BZD use among all BZD users.Age (b = 0.130) and
chronic illnesses (b = 0.120) were significantly associated
with higher inappropriate BZD use. Higher scores on
agreeableness were associated with lower inappropriate
use (b = -0.111).
Discussion
BZDs were used by a considerable proportion of the 2852
NESDA participants (15.0%). BZD use was independently
associated with older age, singleness, unemployment,
treatment in secondary care, high medical consumption
(more severe) anxiety, depression, comorbidity (more
severe) insomnia and antidepressant use. Inappropriate
BZD use was independently associated with older age and
chronic illnesses. High scores on agreeableness were
correlates of less inappropriate use. Overall, BZD use was
rarely in accordance with all guidelines, mainly because
most users (82.5%) exceeded the recommended maxi-
mum duration for safe use.
Although the uncritical enthusiasm about BZD use has
been over for many decades [30, 47, 48], BZDs are still not
only used for the treatment of severe insomnia and anxiety
(other than epilepsy), but also to alleviate stress caused by
adverse life circumstances such as unemployment [49] as
well as pain [6] and other somatic complaints [1]. Largely
corresponding to earlier findings, our results show that
mainly the physically and mentally more vulnerable, e.g.
the old [5, 13, 29], unemployed [12, 13, 15], psychologically
[3, 13, 15–17, 32–34] and physically [14, 18, 34] ill subjects
are using BZDs and use these BZDs inappropriately. There
seems to be a tendency from relatively non-vulnerable
subjects being non-users, mildly vulnerable being users
and highly vulnerable being inappropriate users. Consis-
tently, vulnerable subjects reported lower perceived
support [50–52] as well as more maladaptive coping strat-
egies [18, 32, 50, 51, 53] and were found to display more
emotional arousal when facing stressful events as com-
pared with less vulnerable subjects [49]. They might sub-
stitute those deficits with BZDs [49, 52] and be more likely
to ask their medical doctors (MDs) for tranquillizers to alle-
viate their distress. MDs themselves might also be more
likely to prescribe BZDs to vulnerable subjects as com-
pared with all other problems these people have due to
unemployment, chronic illnesses and psychopathology,
BZD use seems to be the least concerning issue. A number
of qualitative research studies investigated the prescrip-
tion habits of MDs and found that the majority of ques-
tioned MDs were aware of the guidelines [54, 55] and
supported conservative prescription practice of BZDs [54].
A reported reason for prescribing nonetheless was feeling
poorly equipped to solve the emotional problems of their
troubled patients [56], but wanting to alleviate their dis-
tress [55] and maintain a good doctor-patient relationship
[54, 55]. If MDs received more (psychological) education
on how to communicate their reasons for declining
Table 3
Characteristics and adequacy of benzodiazepine (BZD) use (n = 429)
Benzodiazepine use
Type of BZD
Short acting (%, t1/2 < 24 h) 81.1
Long acting (%, t1/2  24 h) 18.9
Mean daily dose (mg day–1)† 2.5 (0.7–6.0)
Duration of use (months) 24.0 (5.0–84.0)
Daily BZD use (%) 38.5













Mean Daily Dose/DDD‡ 1(%) 86.0
Duration of use 3 months (%) 17.5






†Expressed as diazepam equivalents, ‡DDD indicates defined daily dose (DDD for
diazepam: 10 mg day-1), §an inadequacy score of 0 indicates that all adequacy
criteria are met (adequate use), an inadequacy score of 3 indicates that none of the
criteria is met (inappropriate use). Median (interquartile range) is given for mean
daily dose and duration of use. Percentages are given for categorical variables.
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prescriptions to the patients, they might prescribe less and
initiate BZD discontinuation more often [54, 56, 57].
As could be expected, anxiolytic BZDs were more often
used in cases of anxiety disorders and hypnotic BZDs more
often in cases of insomnia. However, it also seems that
the drugs are insufficient to provide therapeutic relief as
otherwise lower anxiety and insomnia scores were to be
expected in the respective groups. Group differences on
age and agreeableness were unexpected and difficult to
explain.
In general, the high percentage of inappropriate users
in NESDA is disconcerting. The majority (84.8%) of users
did not use BZDs according to international guidelines
[25–27], mainly due to exceeding the maximum duration
of recommended use. This is striking considering that for
more than 20 years BZDs have been known to cause side
effects and dependence and evidence for the drug’s effec-
tiveness in long-term use is controversial [7, 8]. In addition,
several NESDA subjects surpassed the recommended daily
dosage (14.0%) and used more than one type of BZD con-
comitantly (15.6%). Dosage escalation is generally unsafe,
as side effects become more pronounced and can have
adverse consequences ranging from low performance at
work to falls and traffic accidents [6, 20–22]. BZDs should
be reserved for the severely anxious who have tried AD
medication with no effect and have BZDs as a last treat-
ment option. However, BZD prescriptions cannot be dis-
continued without providing patients with alternative
coping strategies. Training should be conducted to
strengthen BZD users’ coping skills [11, 58], self-efficacy
and positive outcome expectations [11] and to lessen their
disengagement beliefs [11] as such efforts may increase
the chance of successful BZD discontinuation [11, 58]. In
spite of all objections and in view of the restricted financial
resources in the health sector, it is clear that prescribing
BZDs takes less time than providing psychological support
[7, 55]. Therefore, BZD use should be targeted with rela-
tively quick and cheap methods that have been developed
(e.g. computer-tailored education [11], discontinuation
letters [59]) and have been found to increase effectively
BZD cessation rates [11, 59].
The present study has some limitations. The cross-
sectional design does not allow us to make causal infer-
ences on whether determinants preceded BZD use or vice
versa. Although participants were asked to bring drug con-
tainers to the interview, one fourth of the subjects did not
adhere to that and reported medication use from memory
leading to a potential recall bias. The 84.8% inappropriate
user number is probably an overestimation, as long-term
users were more likely to be included in the user group
Table 4






Sex (female) -0.003 0.96 0.018 0.72
Age (years) 0.153 0.001 0.130 0.008
Marital status (single) 0.065 0.18
Employment status (not working) 0.114 0.02 0.073 0.14
Education level (years) -0.078 0.11
Health care setting (secondary care) 0.010 0.84
Physical health
Medical consumption -0.043 0.37





MDD only -0.067 0.16
Anxiety only -0.028 0.56
Comorbid disorder 0.060 0.21
IRS 0.013 0.79
BAI 0.075 0.12
IDS-SR mood/cognition scale 0.076 0.12
Personality characteristics
Neuroticism 0.008 0.87
Extraversion -0.113 0.02 -0.043 0.40
Openness -0.098 0.04 -0.065 0.18
Agreeableness -0.126 0.009 -0.111 0.03
Conscientiousness -0.017 0.73
BAI indicates Beck’s anxiety index; IDS-SR indicates Inventory of Depressive Symptomatology Self Report; IRS indicates insomnia rating scale; MDD indicates major depressive disorder;
SSRI indicates selective serotonin re-uptake inhibitor; TCA indicates tricyclic antidepressant. †Inappropriate BZD use is calculated with an inadequacy score. An inadequacy score of
0 indicates that all adequacy criteria are met, an inadequacy score of 3 indicates that none of the criteria is met. Significance is inferred at P < 0.10.
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than short-term users due to the cross-sectional design. A
strong aspect of our study is the conductance of a multi-
variate analysis across a comprehensive set of possible
determinants of BZD use. Furthermore, we included all
aspects of inappropriate BZD use in a large sample com-
posed of subjects with a range of psychopathology.
In conclusion, this study revealed three major points: (1)
the vast majority of NESDA subjects displayed inappropri-
ate BZD use, mainly due to exceeding the maximum dura-
tion of recommended use; (2) it is primarily the physically
or mentally vulnerable subjects who use BZDs; and (3) the
most physically ill of the BZD users are at highest risk for
inappropriate use. Without further evidence for the effec-
tiveness of BZDs in long-term use, caution in initiating BZD
prescriptions is recommended, particularly when patients
are chronically ill and old, as these subjects are most likely
to display inappropriate use.
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